En | De
Sie sind hier: Dermatologie » Tumoren 11. Juli 2020
Erweiterte Suche
Photosensitive Erkrankungen
Kardiovaskuläre Erkrankungen
Muskuloskelettale Erkrankungen
Schrift: Schrift grösser Schrift kleiner

Rect Top
   Seite 1 von 5345  vorhergehende Seite nächste Seite
   Artikel 1 - 20 / 106881  
Mitotically Active Nevus and Nevoid Melanoma: A Clinicopathological and Molecular Study.
Am J Dermatopathol
Mesbah Ardakani N, Singh S, Thomas C, Van Vliet C, Harvey NT, Calonje JE, Wood BA.
PMID: 32649342 [PubMed - as supplied by publisher]

Sex and Gender Disparities in Melanoma.
Cancers (Basel)
Bellenghi M, Puglisi R, Pontecorvi G, De Feo A, Carè A, Mattia G.
PMID: 32645881 [PubMed]

Cancer, Acral Lentiginous Melanoma

Hall KH, Rapini RP, Hall KH, Rapini RP.
PMID: 32644539 [PubMed]

Impact of Non-steroidal Anti-inflammatory Drugs on Recurrence and Survival after Melanoma Surgery: A Cohort Study.
Cancer Invest
Araujo BLC, de Oliveira JL, Rezende JFN, Noguera WS, de Melo AC, Thuler LCS.
PMID: 32643437 [PubMed - as supplied by publisher]

Oncology Nurse Coordinators in Clinical Trials - Shaking up the Melanoma Team.
Asia Pac J Oncol Nurs
Steinberg H.
PMID: 32642495 [PubMed]

Acral Lentiginous Melanoma: A Rare Variant With Unique Diagnostic Challenges.
Brazen BC, Gray T, Farsi M, Miller R.
PMID: 32642340 [PubMed]

Melanoma Epidemiology and Early Detection in Europe: Diversity and Disparities.
Dermatol Pract Concept
Forsea AM.
PMID: 32642304 [PubMed]

T-cell receptor therapy (TCR) against melanoma -immunotherapy for the future?
Scand J Immunol
Winge-Main AK, Wälchli S, Marit Inderberg E.
PMID: 32640053 [PubMed - as supplied by publisher]

Immunotherapy discontinuation - how, and when? Data from melanoma as a paradigm.
Nat Rev Clin Oncol
Robert C, Marabelle A, Herrscher H, Caramella C, Rouby P, Fizazi K, Besse B.
PMID: 32636502 [PubMed - as supplied by publisher]

Reporting regression with melanoma in situ: reappraisal of a potential paradox.
Arch Dermatol Res
Cartron AM, Aldana PC, Khachemoune A.
PMID: 32632620 [PubMed - as supplied by publisher]

Consensus Guidelines for the Management of Melanoma during the COVID-19 Pandemic: Surgery, Systemic Anti-cancer Therapy, Radiotherapy and Follow-up.
Clin Oncol (R Coll Radiol)
Nahm SH, Rembielak A, Peach H, Lorigan PC, Contributing Clinicians..
PMID: 32631767 [PubMed - as supplied by publisher]

Cell-Mediated Release of Nanoparticles as a Preferential Option for Future Treatment of Melanoma.
Cancers (Basel)
Chillà A, Margheri F, Biagioni A, Del Rosso T, Fibbi G, Del Rosso M, Laurenzana A.
PMID: 32630815 [PubMed]

Chitosan-Based Delivery of Avian Reovirus Fusogenic Protein p10 Gene: In Vitro and In Vivo Studies towards a New Vaccine against Melanoma.
Biomed Res Int
Robles-Planells C, Barrera-Avalos C, Rojo LE, Spencer E, Cortez-San Martin M, Matiacevich S, Pavez J, Milla LA, Navarro FD, Martínez BA, Bravo FJ, Mella A, Huidobro-Toro JP, Fernandez R, Escobar A, Castillo CA.
PMID: 32626742 [PubMed - in process]

Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma.
Front Cell Dev Biol
Yeon M, Kim Y, Jung HS, Jeoung D.
PMID: 32626712 [PubMed]

The MelFo Study UK: Effects of a Reduced-Frequency, Stage-Adjusted Follow-Up Schedule for Cutaneous Melanoma 1B to 2C Patients After 3-Years.
Ann Surg Oncol
Moncrieff MD, Underwood B, Garioch JJ, Heaton M, Patel N, Bastiaannet E, Hoekstra-Weebers JEHM, Hoekstra HJ.
PMID: 32623608 [PubMed - as supplied by publisher]

A Retrospective Multicenter Study of Fatal Pediatric Melanoma.
J Am Acad Dermatol
Hawryluk EB, Moustafa D, Bartenstein D, Brahmbhatt M, Cordoro K, Gardner L, Gauthier A, Grossman D, Gupta D, Hunt RD, Jen M, Kao PC, Kruse LL, Lawley LP, London WB, Mansour D, O'Haver JA, Phung T, Pope E, Price HN, Rogers T, Shah SD, Wolner Z, Huang J, Marghoob AA.
PMID: 32622142 [PubMed - as supplied by publisher]

Early Phase of Primary Melanoma Growth from the Patient Point of view: A Prospective Cross Sectional Study on Melanoma over 1 mm in Thickness.
Acta Derm Venereol
Malissen N, Abed S, Macagno N, Amatore F, Loundou A, Grange F, Gaudy-Marqueste C, Grob JJ.
PMID: 32618351 [PubMed - as supplied by publisher]

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations.
Ther Adv Med Oncol
Giunta EF, De Falco V, Napolitano S, Argenziano G, Brancaccio G, Moscarella E, Ciardiello D, Ciardiello F, Troiani T.
PMID: 32612709 [PubMed]

Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover.
Cancers (Basel)
Lebbé C, Dutriaux C, Lesimple T, Kruit W, Kerger J, Thomas L, Guillot B, Braud F, Garbe C, Grob JJ, Loquai C, Ferraresi V, Robert C, Vasey P, Conry R, Isaacs R, Espinosa E, Schueler A, Massimini G, Dréno B.
PMID: 32610581 [PubMed]

Characterization of uveal melanoma clinical trial design: a systematic review to establish an elusive standard of care.
Acta Oncol
Zhang HG, Moser JC, Dalvin LA.
PMID: 32609032 [PubMed - as supplied by publisher]

   Artikel 1 - 20 / 106881    Seite 1 von 5345  vorhergehende Seite nächste Seite

Rect Bottom
Adserver Footer





Haben Sie Ihr Passwort vergessen?


Neu bei My Medline?

Melden Sie sich bei My Medline an!


Mehr über My Medline erfahren

mehr >>


Benutzen Sie englische Suchbegriffe für Ihre Suche in medline.ch.



mehr >>


Sky right 1